DITROPAN
LOE ApproachingNDAORALTABLET
Approved
Jul 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DITROPAN by Johnson & Johnson is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency and 2 more indications. First approved in 1975.
Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DITROPAN (oxybutynin chloride) is an oral anticholinergic small molecule that treats overactive bladder by relaxing bladder smooth muscle and increasing bladder capacity. It works by inhibiting muscarinic acetylcholine action, reducing involuntary detrusor contractions and decreasing urgency and incontinence frequency. The drug has been approved since 1975 and is indicated for adults and pediatric patients aged 6+ with overactive bladder or neurological detrusor overactivity.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30%), indicating shift from growth to maintenance strategies and potential team restructuring.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on DITROPAN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.